Gastroenterology is a medical specialty focusing on the structure, function, pathology and disorders of the gastrointestinal system. Gastroenterologists investigate, diagnose, treat and prevent all gastrointestinal (stomach and intestines) and herpetological (liver, gallbladder, biliary tree and pancreas) diseases.
The field of gastroenterology will change dramatically on several fronts over the next 10 years. Many doctors are trying to keep up with the pace of change in the structure of practices. Realignments and the decline of office-based private practice have been rapid and dramatic. We live in an era of health system empowerment and many physicians are struggling to adjust. Technological and therapeutic advances will also alter the landscape. There is little doubt that our approach to everyday diagnoses will evolve whether it be colorectal cancer screening, therapies for inflammatory bowel disease or our understanding of the gut microbiome. Colonoscopy will still play a major role, although its place in screening for colon cancer may change. Another change will be in our understanding of the gut biome. Manipulation of our gut bacteria will become routine in treating an assortment of disorders, including obesity and perhaps mental disorders like depression. This will become a routine aspect of gastroenterology, just as the treatment of peptic ulcer disease with antibiotics became the norm in the past 20 years.
The market size for gastrointestinal therapeutics is set to grow from $35.7 billion in 2015 to $48.4 billion by 2022, representing a compound annual growth rate of 4.45%. On the basis of geography, the global gastrointestinal drugs market is expected to be led by North America. Favorable reimbursement policies, and increasing geriatric population, who are more prone to gastrointestinal disorders, will drive the region’s growth during the forecast period from 2016 to 2024. North America held 41% of the market in 2016. Europe has also been witnessing healthy growth and is anticipated to continue being an attractive region for gastrointestinal drugs market. “The emergence of biosimilars for treating inflammatory bowel diseases will also be a key growth driver for the market in Europe. The growing investments and funding in the field of life science research and advanced therapies for the treatment of gastrointestinal diseases in developing nations such as China and India will fuel the growth of the Asia Pacific market.
The University of Tokyo, Japan; National University of Singapore (NUS), Singapore; University of Hong Kong (HKU), Hong Kong; Peking University, China; Seoul National University (SNU), South Korea
King Saud University, Saudi Arabia; Cairo University, Egypt; Hebrew University of Jerusalem, Israel; Qatar University, Qatar; American University of Sharjah, UAE
LMU Munich, Germany; University of Leuven, Belgium; University of Amsterdam, Netherlands; RWTH Aachen University, Germany; University of Groningen, Netherland
Harvard University, USA; Johns Hopkins University, USA; Washington University in St. Louis, USA; McGill University, Canada; University of Toronto, Canada
Global Research Centers:
Asian Institute of Gastroenterology, India; Institute for Clinical Sciences (SICS), Singapore; Endoscopy Asia, India; Tohoku Research Centre, Japan; Clinical Research Institute of Diabetes in Changsha, China
Harvard Medical School Center for Global Health Delivery, Dubai; Columbia University Middle East Research Center, Jordan; Sidra Medical Research Centre, Qatar; Dubai Specialized Medical Center & Medical Research Labs, UAE; Research Institute of Medical & Health Sciences, UAE
World Gastroenterology Organisation, Austria; EAGEN - European Association for Gastroenterology, Germany; Research Center of Gastroenterology and Hepatology, Romania; European Society of Gastrointestinal Endoscopy, France; United European Gastroenterology, Austria
Research in Gastroenterology & Hepatology, USA; Gastroenterology Research, Boston, USA; Digestive Diseases Research Core Centers, USA; American Gastroenterological Association, USA; Canadian Association of Gastroenterology, Canada
Gleneagles Global Hospitals, India; Mahkota Medical Centre, Malaysia; Bangkok Hospital Pattaya, Thailand; Roland Chong Gastroenterology & Medical Pte Ltd, Singapore; Parkway Health, China
Koc University Hospital, Turkey; Rambam Medical Center, Israel; Ahalia Hospital, UAE
Naseem Al Rabeeh Medical Centre, Qatar; Jordan Hospital, Jordan
Grupo Hospitalario Quirón, Spain; Klinik Hirslanden & Klinik Im Park, Switzerland; SARAFIANOS Private Clinic, Greece; Clinique de L'Alma, France; University Hospital Heidelberg, Germany
Mount Sinai – Gastroenterology, USA; USA Pediatric Gastroenterology, USA; UNC Gastroenterology, USA; Sunnybrook Health Sciences Centre, Canada; Mount Sinai Hospital, Canada
Ordain Health Care Global Private Limited, India; Takeda Singapore Pte Limited. Singapore; Janssen Pharma, Japan; Pax Healthcare - Pharma PCD Company, China; Natco Pharma Limited, India
Bayer Middle East FZE, UAE; CAD Middle East Pharmaceutical Industries LLC, Saudi Arabia; QatarPharma, Qatar; Leo Pharma, Dubai; Mediclinic Pharmacy, UAE
Norgine BV, Netherlands; Otsuka Europe, England; InDex Pharmaceuticals AB, Sweden; Tillotts Pharma AG, Switzerland; Sigmoid Pharma Limited, Ireland
Alvogen, USA; Ritter Pharmaceuticals Inc, USA; Gedeon Richter Mexico, Mexico; Purdue Pharma, Canada; Astellas Pharma, Canada